134 related articles for article (PubMed ID: 29069749)
1.
Riedl S; Rinner B; Schaider H; Liegl-Atzwanger B; Meditz K; Preishuber-Pflügl J; Grissenberger S; Lohner K; Zweytick D
Oncotarget; 2017 Sep; 8(42):71817-71832. PubMed ID: 29069749
[TBL] [Abstract][Full Text] [Related]
2. Killing of melanoma cells and their metastases by human lactoferricin derivatives requires interaction with the cancer marker phosphatidylserine.
Riedl S; Rinner B; Schaider H; Lohner K; Zweytick D
Biometals; 2014 Oct; 27(5):981-97. PubMed ID: 24838743
[TBL] [Abstract][Full Text] [Related]
3. Interaction of two antitumor peptides with membrane lipids - Influence of phosphatidylserine and cholesterol on specificity for melanoma cells.
Wodlej C; Riedl S; Rinner B; Leber R; Drechsler C; Voelker DR; Choi JY; Lohner K; Zweytick D
PLoS One; 2019; 14(1):e0211187. PubMed ID: 30682171
[TBL] [Abstract][Full Text] [Related]
4. Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine.
Riedl S; Leber R; Rinner B; Schaider H; Lohner K; Zweytick D
Biochim Biophys Acta; 2015 Nov; 1848(11 Pt A):2918-31. PubMed ID: 26239537
[TBL] [Abstract][Full Text] [Related]
5. Design of human lactoferricin derived antitumor peptides-activity and specificity against malignant melanoma in 2D and 3D model studies.
Grissenberger S; Riedl S; Rinner B; Leber R; Zweytick D
Biochim Biophys Acta Biomembr; 2020 Aug; 1862(8):183264. PubMed ID: 32151609
[TBL] [Abstract][Full Text] [Related]
6. Effect of L- to D-Amino Acid Substitution on Stability and Activity of Antitumor Peptide RDP215 against Human Melanoma and Glioblastoma.
Maxian T; Gerlitz L; Riedl S; Rinner B; Zweytick D
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445175
[TBL] [Abstract][Full Text] [Related]
7. Lectin-anticancer peptide fusion demonstrates a significant cancer-cell-selective cytotoxic effect and inspires the production of "clickable" anticancer peptide in Escherichia coli.
Pasupuleti R; Riedl S; Saltor Núñez L; Karava M; Kumar V; Kourist R; Turnbull WB; Zweytick D; Wiltschi B
Protein Sci; 2023 Dec; 32(12):e4830. PubMed ID: 37916438
[TBL] [Abstract][Full Text] [Related]
8. In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis.
Wußmann M; Groeber-Becker FK; Riedl S; Alihodzic D; Padaric D; Gerlitz L; Stallinger A; Liegl-Atzwanger B; Zweytick D; Rinner B
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428530
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of endotoxin neutralization by coupling of a C12-alkyl chain to a lactoferricin-derived peptide.
Andrä J; Lohner K; Blondelle SE; Jerala R; Moriyon I; Koch MH; Garidel P; Brandenburg K
Biochem J; 2005 Jan; 385(Pt 1):135-43. PubMed ID: 15344905
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of synthetic cationic peptides and lipopeptides derived from human lactoferricin against Pseudomonas aeruginosa planktonic cultures and biofilms.
Sánchez-Gómez S; Ferrer-Espada R; Stewart PS; Pitts B; Lohner K; Martínez de Tejada G
BMC Microbiol; 2015 Jul; 15():137. PubMed ID: 26149536
[TBL] [Abstract][Full Text] [Related]
11. Melanoma cell surface-expressed phosphatidylserine as a therapeutic target for cationic anticancer peptide, temporin-1CEa.
Wang C; Chen YW; Zhang L; Gong XG; Zhou Y; Shang DJ
J Drug Target; 2016; 24(6):548-56. PubMed ID: 26596643
[TBL] [Abstract][Full Text] [Related]
12. Human melanoma brain metastases cell line MUG-Mel1, isolated clones and their detailed characterization.
Heitzer E; Groenewoud A; Meditz K; Lohberger B; Liegl-Atzwanger B; Prokesch A; Kashofer K; Behrens D; Haybaeck J; Kolb-Lenz D; Koefeler H; Riedl S; Schaider H; Fischer C; Snaar-Jagalska BE; de'Jong D; Szuhai K; Zweytick D; Rinner B
Sci Rep; 2019 Mar; 9(1):4096. PubMed ID: 30858407
[TBL] [Abstract][Full Text] [Related]
13. Casticin Induced Apoptosis in A375.S2 Human Melanoma Cells through the Inhibition of NF-[Formula: see text]B and Mitochondria-Dependent Pathways In Vitro and Inhibited Human Melanoma Xenografts in a Mouse Model In Vivo.
Shiue YW; Lu CC; Hsiao YP; Liao CL; Lin JP; Lai KC; Yu CC; Huang YP; Ho HC; Chung JG
Am J Chin Med; 2016; 44(3):637-61. PubMed ID: 27109154
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of benzyl-isothiocyanate inhibits in vivo growth of subcutaneous xenograft tumors of human malignant melanoma A375.S2 cells.
Ni WY; Hsiao YP; Hsu SC; Hsueh SC; Chang CH; Ji BC; Yang JS; Lu HF; Chung JG
In Vivo; 2013; 27(5):623-6. PubMed ID: 23988897
[TBL] [Abstract][Full Text] [Related]
15. Influence of N-acylation of a peptide derived from human lactoferricin on membrane selectivity.
Zweytick D; Pabst G; Abuja PM; Jilek A; Blondelle SE; Andrä J; Jerala R; Monreal D; Martinez de Tejada G; Lohner K
Biochim Biophys Acta; 2006 Sep; 1758(9):1426-35. PubMed ID: 16616888
[TBL] [Abstract][Full Text] [Related]
16. Enhanced in-vitro and in-vivo suppression of A375 melanoma by combined IL-24/OSM adenoviral-mediated gene therapy.
Xu Y; Zhang F; Qin L; Miao J; Sheng W; Xie Y; Xu X; Yang J; Qian H
Melanoma Res; 2014 Feb; 24(1):20-31. PubMed ID: 24300090
[TBL] [Abstract][Full Text] [Related]
17. Bridging the Antimicrobial Activity of Two Lactoferricin Derivatives in
Marx L; Semeraro EF; Mandl J; Kremser J; Frewein MP; Malanovic N; Lohner K; Pabst G
Front Med Technol; 2021; 3():625975. PubMed ID: 35047906
[TBL] [Abstract][Full Text] [Related]
18. Enhancing melanoma treatment with resveratrol.
Osmond GW; Augustine CK; Zipfel PA; Padussis J; Tyler DS
J Surg Res; 2012 Jan; 172(1):109-15. PubMed ID: 20855085
[TBL] [Abstract][Full Text] [Related]
19. Genetically engineered mesenchymal stromal cells producing TNFα have tumour suppressing effect on human melanoma xenograft.
Tyciakova S; Matuskova M; Bohovic R; Polakova K; Toro L; Skolekova S; Kucerova L
J Gene Med; 2015; 17(1-2):54-67. PubMed ID: 25677845
[TBL] [Abstract][Full Text] [Related]
20. The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo.
Eliassen LT; Berge G; Leknessund A; Wikman M; Lindin I; Løkke C; Ponthan F; Johnsen JI; Sveinbjørnsson B; Kogner P; Flaegstad T; Rekdal Ø
Int J Cancer; 2006 Aug; 119(3):493-500. PubMed ID: 16572423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
